According to the data provided by the Synapse Database, As of November 16, 2023, there are 303 investigational drugs for the GLP-1R and integrin target, including 72 indications, 276 R&D institutions involved, with related clinical trials reaching 2510, and as many as 7224 patents
While weekly options like Semaglutide and Tirzepatide are more common in 2026, a daily option like Liraglutide might be chosen due to insurance coverage, specific patient history, or formulary preferences
Swelling of the treated areas Severe burning, itching Crusting (formation of dried serum, blood or pus on the surface of the skin) Contact dermatitis (rash) Halo spots (the areas surrounding the dark spots come in contact with the product, and thus, they lighten
Monitoring during early treatment is important
Retatrutide's glucagon activity adds small, dose-related increases in heart rate and glucose seen in trials